PMID- 25055558
OWN - NLM
STAT- MEDLINE
DCOM- 20140930
LR  - 20191112
IS  - 0869-6047 (Print)
IS  - 0869-6047 (Linking)
IP  - 1-2
DP  - 2014
TI  - [Correlation between concentration of pathological cytokines and erythropoietin 
      in patients with chronic heart failure with anemic syndrome].
PG  - 32-7
AB  - AIM: To study correlation between concentration of pathological cytokines and 
      erythropoietin inpatients with chronic heart failure anemic syndrome and also to 
      prove importance of this communication for need of appointment erythropoietin 
      excitants. PATIENTS AND METHODS: 94 patients with chronic heart failure of New 
      York Heart Association (NYHA) class III-IV a left ventricular ejection fraction 
      of 40% or less withanemia w ere idied in inveslain (58 males, 36 females). Anemia 
      was detected when hemoglobin (b) was less than 120 g/l in males and less than in 
      females. 46 patients received traditional treatment of CHF (I group) and 48 
      patients were treated additionally with erythropoietin (EPO) (II group). 
      Percutaneous EPO 50 IU monthly to patients without iron deficiency for a period 
      of 6 months. Echocardiography parameters, plasma NT and pro-BNP, cytokines, EPO, 
      feritin and 6-minute walking test were assessed at baseline and after treatment. 
      RESULT: in patients with CHF and anemia in II group erythropoietin treatment 
      increased Hb levels by 22.4% (p < 0.05) and erythropoietin serum levels by 29.3 
      +/- 14.3 IU/ml (p < 0.001). Increased erythropoietin level was associated with 
      decrease of cytokines levels: IL 1 by 36.6% (p < 0.001), IL 6 by 54.3% (p < 
      0.05), TNF alpha by 48.3% (p < 0.05) compared with patients in I group. In 
      erythropoietin-treated patients there is a significant increase of LVEF by 19.04% 
      (p < 0.05) compared with patients from I group. A greater 6-minute distance 
      walked on exercise testing increased by 76.6% (p < 0.05) after treatment with 
      erythropoieitin. CONCLUSIONS: Correction of anemia in patients with chronic heart 
      failure with percutaneous erythropoietin injections 50 IU monthly for 6 month 
      period to improve erythropoietin deficit and cytokines aggression and associated 
      anemia, symptoms and quaity of life.
FAU - Zakhidova, K Kh
AU  - Zakhidova KKh
LA  - rus
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Vestn Ross Akad Med Nauk
JT  - Vestnik Rossiiskoi akademii meditsinskikh nauk
JID - 9215641
RN  - 0 (Cytokines)
RN  - 0 (EPO protein, human)
RN  - 0 (Hemoglobins)
RN  - 0 (Interleukin-1)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11096-26-7 (Erythropoietin)
RN  - 64FS3BFH5W (Epoetin Alfa)
SB  - IM
MH  - Anemia/*blood/*drug therapy/etiology
MH  - Chronic Disease
MH  - Cytokines/*blood
MH  - Epoetin Alfa
MH  - Erythropoietin/*blood/*therapeutic use
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/*blood/complications/drug therapy
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Interleukin-1/blood
MH  - Male
MH  - Middle Aged
MH  - Recombinant Proteins/therapeutic use
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Ventricular Function, Left
EDAT- 2014/07/25 06:00
MHDA- 2014/10/01 06:00
CRDT- 2014/07/25 06:00
PHST- 2014/07/25 06:00 [entrez]
PHST- 2014/07/25 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
AID - 10.15690/vramn.v69i1-2.939 [doi]
PST - ppublish
SO  - Vestn Ross Akad Med Nauk. 2014;(1-2):32-7. doi: 10.15690/vramn.v69i1-2.939.